Browsing Over 990 Presentations

Sort By

Panel discussion on management of mBC in Asian patients (ID 1793)

South Korea’s journey with precision oncology (ID 1798)

Is immuno-oncology going to replace chemotherapy in advanced HNSCC? (ID 1803)

Charting the course for the stage III NSCLC patient (ID 1780)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

Conclusion

Lecture Time
02:05 PM - 02:10 PM
Session Name
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM

What’s new in metastatic pancreatic cancer management? (ID 1785)

Introduction of Speaker (ID 1791)

The clinical significance of comprehensive genomic profiling (ID 1796)

Expert Opinion on ‘PARP inhibitors as targeted therapy for personalized medicine’ - Panel Discussion (ID 1882)

Welcome, introductions and objectives of the session (ID 1801)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

Future development for the use of biomarkers

Lecture Time
01:40 PM - 02:05 PM
Session Name
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Speakers
  • Ross A. Soo
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
  • Ross A. Soo

Introduction (ID 1783)